Reuters logo
4 个月内
BRIEF-TapImmune announces fully funded phase 2 clinical study of HER2-targeted vaccine
2017年3月14日 / 晚上6点09分 / 4 个月内

BRIEF-TapImmune announces fully funded phase 2 clinical study of HER2-targeted vaccine

1 分钟阅读

March 14 (Reuters) - TapImmune Inc :

* Announces fully funded phase 2 clinical study of HER2-targeted vaccine in early breast cancer

* Study is expected to begin in 2017

* Collaborators at Mayo Clinic, received $3.7 million grant from U.S. DoD to conduct phase 2 clinical study on TapImmune's HER2/neu-targeted T-cell vaccine

* Co will be funded for providing manufactured product for this trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below